Life Science REIT plc

BATS-CHIXE:LABSL Stock Report

Market Cap: UK£134.4m

Life Science REIT Past Earnings Performance

Past criteria checks 0/6

Life Science REIT's earnings have been declining at an average annual rate of -37.2%, while the Health Care REITs industry saw earnings growing at 5% annually. Revenues have been growing at an average rate of 4.3% per year.

Key information

-37.2%

Earnings growth rate

-37.2%

EPS growth rate

Health Care REITs Industry Growth7.7%
Revenue growth rate4.3%
Return on equity-15.0%
Net Margin-199.0%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Life Science REIT makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BATS-CHIXE:LABSL Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2420-4050
31 Mar 2420-3150
31 Dec 2320-2250
30 Sep 2320-2550
30 Jun 2319-2950
31 Mar 2318-2860
31 Dec 2216-2860
31 Dec 2111920

Quality Earnings: LABSL is currently unprofitable.

Growing Profit Margin: LABSL is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if LABSL's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare LABSL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LABSL is unprofitable, making it difficult to compare its past year earnings growth to the Health Care REITs industry (29.2%).


Return on Equity

High ROE: LABSL has a negative Return on Equity (-14.98%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies